ArticleBMC geriatrics2026
Development and external validation of a sarcopenia risk prediction model in elderly patients with heart failure with preserved ejection fraction.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChronic heart failure combined with sarcopenia is significantly associated with negative health outcomes in elderly patients. Therefore, early identification of sarcopenia risk in elderly patients with heart failure is crucial for their prognosis, however, there is currently no simple and practical predictive model available for clinicians.This study aimed to develop and externally validate a risk prediction model for sarcopenia in elderly patients with heart failure with preserved ejection fraction.
methodsA retrospective study design was employed.A cohort of HFpEF patients from the Geriatrics Department of Ruijin Hospital was used as the development cohort (n = 272) for model construction and internal validation.Variables with significant differences in intergroup comparisons were initially screened, followed by variable compression using LASSO regression.A multivariable logistic regression analysis was ultimately performed to establish the prediction model.The discriminative ability and calibration of the model were assessed using ROC curve and calibration curve, respectively.Subsequently, an independent external validation cohort (n = 84) from Nursing Home in Changning District was used to validate the model’s generalizability and clinical utility through ROC curve analysis, calibration curve analysis, and decision curve analysis.
resultsThe final model included five predictors: 1, 25OH-VitD3, BMI, NRS2002 score, handgrip strength, and homocysteine. In the development cohort, the model showed strong discriminative ability, with an AUC of 0.923 (95% CI: 0.892–0.954), and was well-calibrated. External validation confirmed its robust performance, yielding an AUC of 0.937 (95% CI: 0.890–0.984). The calibration curve indicated high agreement between predictions and observations, and decision curve analysis demonstrated a favorable net clinical benefit.
conclusionsThis study developed and validated the first risk prediction model for sarcopenia tailored to elderly HFpEF patients. The model performed excellently in both internal and external validation, enabling effective identification of high-risk individuals. It offers a practical quantitative tool for early screening and targeted intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.